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of SCT-ineligible patients; in second-line (post-onset of relapsed/refractory MM), 
lenalidomide/dexamethasone (33%) and bortezomib/dexamethasone (15%) were 
most common for patients previously receiving SCT (similar results reported for 
patients not receiving SCT). More than half of physicians estimated that typical 
second-line treatment duration is < 6 months, with progression cited (~75% of 
respondents) as the main reason for second-line discontinuation. For high-risk 
patients, 52% of physicians judged median survival to be < 10 months from RRMM 
onset. CONCLUSIONS: Bortezomib-based regimens are the predominant choice of 
first-line MM treatment; while bortezomib is also frequently chosen in second-line 
(post-RRMM onset), lenalidomide-based regimens are the most common. Survival 
prospects for RRMM patients remain limited, particularly for high-risk patients, 
and second-line therapy is typically of short duration (< 6 months). Patient-level 
studies are needed to formally characterize unmet medical needs suggested in 
our findings for European RRMM patients.
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OBJECTIVES: Initial endocrine therapy (ET) is preferred for most post-menopausal 
women with hormone receptor positive human epidermal growth factor receptor 
2 negative metastatic breast cancer (HR+/HER2- mBC), and guidelines recommend 
reserving chemotherapy (CT) for patients with symptomatic visceral disease or no 
clinical benefit after 3 sequential ET regimens. This study describes treatment pat-
terns among post-menopausal HR+/HER2- mBC patients previously treated with 
adjuvant therapy (recurrent patients) or not (de novo patients). METHODS: Charts 
from a network of US community-based oncology practices were reviewed for 
post-menopausal women with HR+/HER2- mBC who progressed to mBC between 
1/1/2004 and 9/30/2010. Extracted chart data included demographic characteristics, 
treatment history, and outcomes. RESULTS: Patients (n= 144) had a median age of 
65 years at mBC diagnosis. They received a median of 2 lines of ET, and < 10% had 
3 or more lines of ET before receiving CT. De novo patients (n= 69) and recurrent 
patients (n= 75) received a median of 2 lines and 1 line of ET, respectively. The 
recurrent group had a lower proportion of patients receiving 1st-line single agent 
ET compared with the de novo group (65% vs. 71%). Unlike de novo patients, who 
had non-steroidal aromatase inhibitors (NSAIs) as the most frequent 1st-line ET 
(letrozole (35%), anastrozole (26%)), recurrent patients predominantly received 
fulvestrant (23%) in the 1st-line setting, possibly due to prior adjuvant NSAI. In 
addition, a higher proportion of recurrent patients received CT as 1st-line therapy 
compared with de novo patients (27% vs. 20%). CONCLUSIONS: The majority of 
de novo patients received 1st-line NSAIs, but recurrent patients were less likely 
to receive NSAIs and more likely to receive 1st-line CT. Recurrent patients also 
received fewer total lines of ET. Most mBC patients did not receive the guideline-
recommended 3 lines of ET. The unmet need for improved ET options was par-
ticularly pronounced among recurrent patients.
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OBJECTIVES: To evaluate the efficacy and safety of FDA-approved biologics for 
moderate-to-severe Crohn’s disease (CD). METHODS: We conducted a literature 
search using PubMed, EMBASE, and Cochrane library, and identified articles from 
inception to October 10, 2014. The combination of search terms included: “inflixi-
mab,” “adalimumab,” “certolizumab pegol,” “vedolizumab,” and “Crohn’s disease.” 
Studies were selected if they were randomized placebo-controlled trials > /= 50 
weeks of follow-up; that evaluated one or more biologics of interest, provided 
results about clinical remission (defined as CD Activity Index< 150 points), serious 
infections and/or serious adverse events; and was conducted in adults. The princi-
pal aim was to compare clinical remission at the end of the study period between 
biologics. Secondary aims included the probability of experiencing a serious infec-
tion or serious adverse event. Bayesian network meta-analyses were performed 
to synthesize results; and comparisons were summarized using odds ratios (OR) 
and 95% credible intervals (CrI). RESULTS: Among 324 articles identified, 11 met 
inclusion criteria. The odds of achieving clinical remission were greater with adali-
mumab than with vedolizumab (OR= 1.33; 95%CrI: 0.67-2.42), infliximab (OR= 1.40; 
95%CrI: 0.86-2.53) and certolizumab pegol (OR= 1.23; 95%CrI: 0.72-2.29); all not 
statistically significant. Similarly, the odds of clinical remission were greater with 
certolizumab pegol than with vedolizumab (OR= 0.91; 95%CrI: 0.48-1.60) and inf-
liximab (OR= 1.18; 95%CrI: 0.68-1.92); all not statistically significant. Certolizumab 
pegol had the highest probability of serious infections (0.053%) followed by ved-
olizumab (0.022%), infliximab (0.010%), and adalimumab (0.008%). Vedolizumab 
had the highest probability of serious adverse events (19%) followed by certoli-
zumab pegol (10%), infliximab (10%), and adalimumab (7%). CONCLUSIONS: We 
did not find any statistically significant differences between biologics in clinical 
remission, serious infections, and serious adverse events, which highlights the 
importance for comparative effectiveness research (CER) in this area. CER will be 
able to guide clinical and formulary decision-makers in selecting biologics with 
high value for CD.
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OBJECTIVES: Colorectal cancer (CRC) ranks third in prevalence and cancer deaths 
among all cancers in the United States. Nearly one fourth of CRC patients are diag-
nosed at metastatic stage (mCRC), which has a poor prognosis and an overall survival 
of 5% to 8% at five years. Over the last decade multiple chemotherapies and targeted 
biologics have been approved for mCRC and patients receive an array of these treat-
ments in various combinations, with limited evidence. The study examines current 
usage patterns by line of treatment for elderly mCRC patients. METHODS: A retro-
spective observational cohort study was conducted for mCRC patients diagnosed 
from January 2004 through December 2009 using the Surveillance Epidemiology 
and End Results-Medicare linked database. Systemic chemotherapies and targeted 
biologics currently approved by the Food and Drug Administration for treatment 
of mCRC patients were included. The first three lines of treatment administered to 
elderly mCRC patients were empirically identified. RESULTS: The most common 
first line of treatment for mCRC patients (n= 4,603) was bevacizumab + fluorouracil 
+ oxaliplatin (24%), followed by fluorouracil + oxaliplatin (23%). Bevacizumab + fluo-
rouracil + oxaliplatin (18%) and bevacizumab + fluorouracil + irinotecan (15%) were 
the most administered second line of treatments, while cetuximab + irinotecan and 
bevacizumab + fluorouracil + irinotecan were the commonly administered third line 
regimens (15% each). Of 4,603 mCRC patients who received first a line of treatment, 
2,708 (59%) continued to receive a second line of treatment, 1,480 (32%) received 
a third line of treatment, and 1,895 (41%) did not receive any further line of treat-
ment. CONCLUSIONS: In accordance with current recommendations and previous 
studies, fluorouracil + oxaliplatin/irinotecan based regimens with bevacizumab 
were the most common first and second line treatments. Further exploration of the 
comparative effectiveness of line of treatments sequencing may yield important 
information for improving the quality of cancer treatment.
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OBJECTIVES: Little data from real-world clinical settings in Europe are available 
describing treatment patterns and survival of relapsed/refractory multiple mye-
loma (RRMM) patients. This study begins to address this knowledge gap using data 
from a brief physician survey. METHODS: A cross-sectional survey of 61 physicians 
treating RRMM in France (n= 21), Germany (n= 20), and the United Kingdom (n= 20) 
was conducted in November 2014. The survey collected physicians’ opinions on 
typical treatment patterns and survival of RRMM patients in the relapse/refrac-
tory setting (i.e., following disease progression during/after completion of first-
line therapy). Analyses were descriptive. RESULTS: Specialty distribution among 
the respondents was 44% hematology, 51% onco-hematology, and 5% medical 
oncology. Teaching hospitals were the most common practice setting (59%). The 
respondents’ mean (SD) past-year multiple myeloma (MM) caseload was 53.0 (33.0) 
patients (range: 12-150); 21% of these patients were reported to have high-risk 
disease based on ISS stage and cytogenetics. Bortezomib-based regimens were 
first-line treatment for 73% of stem cell transplant (SCT)-eligible patients and 60% 
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model. Subgroup and sensitivity analysis was also performed. RESULTS: Seven RCTs 
including 2110 HP positive patients were included in final analysis. Significant het-
erogeneity was observed for effectiveness (Cochran Q, P - < 0.012, I2 > 50%) and ADRs 
(Cochran Q, P- < 0.095, I2 > 50%). No significant publication bias was observed. TT was 
more effective (RR 0.69 (95% CI, 0.63-0.76)) than DT. TT was also well tolerated (RR, 
0.80 (95% CI, 0.41-1.54)) in comparison to DT. Results were not sensitive to various 
subgroup and sensitivity analysis. CONCLUSIONS: TT is found to be more effective 
and safe in comparison to DT for eradication of Helicobacter pylori.
Pgi5
The amelioraTioN of doxoruBiCiN-iNduCed oxidaTive liver iNjury By 
ursodeoxyCholiC aCid
Stanimirov B., Stankov K., Pavlovic N., Stojancevic M., Vukmirovic S., Mikov M.
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
OBJECTIVES: The overproduction of free radicals is considered as a significant cause 
hepatotoxicity of doxorubicin, overshadowing its, otherwise, highly potent anti-
neoplastic effectiveness. of its side effects. The aim of our study was to evaluate the 
potential hepatoprotective properties of ursodeoxycholic acid (UDCA), its influence 
on lipid peroxidation (LPO) and expression of glutathione-dependent antioxida-
tive enzymes in the livers of rats treated with DOX. METHODS: Twenty four male 
Wistar rats were divided in four groups. Animals were administered either with 
vehicle (saline i.p. (K1) or saline i.p. with propylene glycol p.o. (K2)), DOX (3 mg/kg 
i.p. every other day for total 3 doses) or combined UDCA 25 mg/kg p.o. every other 
day for total 3 doses, starting one day before administering DOX. On the day 28 
animals were euthanized and the livers were immediately harvested in order to 
determine the expression of selected parameters of oxidative stress. RESULTS: In 
the livers of animals administered with DOX, LPO was increased compared to both 
control groups, whereas in DOX+UDCA group the intensity of LPO was decreased, 
closely to control values. Treatment with DOX significantly increased the specific 
activities of glutathione peroxidase (GPx) compared to control groups (p< 0.01 vs.K1 
and K2). Combined treatment with DOX+UDCA decreased GPx activity. Similarly, 
the activity of glutathione reductase was highest in group treated with DOX and 
lower in group treated with DOX+UDCA. Specific activity of glutathione-S-tran-
ferase was significantly increased in DOX-treated group compared to control groups 
(p< 0.05), and decreased in DOX+UDCA group, however without statistical signifi-
cance. CONCLUSIONS: According to its ability to decrease the LPO and modulate the 
activity of glutathione-dependent antioxidative system, UDCA represents an agent 
with potentially hepatoprotective properties against oxidative liver damage induced 
by high doses of DOX. Acknowledgment: Supported by the Ministry of Education, 
Science and Technological Development, Republic of Serbia, grant No.III41012.
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OBJECTIVES: To determine whether the hybrid therapy (HBD), 14-day-sequential 
therapy (SEQ), and 14-day-concomitant therapy (QAD) result in superiority in terms 
of H. pylori eradication. METHODS: Randomized controlled trials comparing HBD, 
SEQ, and QAD regimens were extracted from a search of PubMed, EMBASE, and 
Cochrane Central Register of Controlled Trials between 1982 and 2014. Dichotomous 
data were pooled to obtained the odds ratio (OR) with 95% confidence intervals 
(CIs). Multivariate random-effects meta-regression was used to estimate the pooled 
effects. The primary outcome was eradication of H. pylori. The secondary outcome 
was overall side effects rate. RESULTS: Six studies were identified. Two compared 
HBD to SEQ, two compared HBD to QAD, and two compared SEQ to QAD. No trial 
compared all three regimens. In intention-to-treat (ITT) analysis, no significant 
superiority was observed among the three regimens in terms of eradication rate 
[HBD compared to SEQ (OR= 0.46, 95 CI: 0.15-1.37), HBD compared to QAD (OR= 
0.96, 95 CI: 0.34-2.70) and SEQ compared to QAD (OR= 2.10, 95 CI 0.67- 6.54)]. By 
ranking probability, HBD had a 49.5% chance of being the most likely regimen to 
achieve eradication, followed by QAD (46.3%). For the side effects, patients taking 
HBD had a significantly higher rate compared to those taking QAD (OR= 5.94, 95 
CI 1.74~20.30). No significant difference was observed when compared QAD to SEQ 
(OR= 0.52, 95 CI: 0.23-1.20), and HBD to SEQ (OR= 0.75, 95 CI: 0.32-1.76). By rank-
ing probability QAD had a 75% chance of being the regimen with the lowest side 
effect rate. CONCLUSIONS: No regimen demonstrated superiority in eradication. 
Considering both eradication rate and side effect rate, QAD should be considered for 
use as first-line therapy in clinical situations with concern for patient adherence.
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OBJECTIVES: To evaluate the role of Ultrasonic scalpel versus electrocautery in 
laparoscopic cholecystectomy (LC) so as to understand how to achieve dissection 
and closure of cystic artery and duct in a safe and efficient approach. METHODS: 
Comparative studies with the subjects of Chinese population were searched till Dec 
2014 in PubMed, EMBASE, Cochrane Library, Chinese Biomedical Database, China 
Academic Journals Full-Text Database, Chinese Scientific Journals Database, and 
China Online Journals. The quality of included studies was evaluated by Handbook 
5.0.0. Cochrane Collaboration’s RevMan 5.0. was used to conduct meta-analysis 
with random effects model. RESULTS: A total of 8 comparative studies (5 RCT and 
3 retrospective comparative studies) were included with 1337 in ultrasonic scalpel 
group and 867 in electrocautery group. In laparoscopic cholecystectomy, compared 
with electrocautery, ultrasonic scalpel shows a statistically significant reduction in 
operation time (weighted mean difference [WMD], -9.38 minutes; 95% confidence 
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OBJECTIVES: Several meta-analyses comparing ciclosporin with immediate-release 
(IR) tacrolimus have been conducted. Only recently have sufficient data become 
available for evidence synthesis including prolonged-release (PR) tacrolimus. In the 
present study, a network meta-analysis (NMA) was conducted to compare the effi-
cacy of ciclosporin, IR and PR tacrolimus in liver transplant recipients. METHODS: 
Systematic literature review of PubMed, EMBASE and the Cochrane Library identified 
randomized controlled trials and large-scale observational studies (≥ 500 patients) 
published since January 2000 comparing IR tacrolimus with PR tacrolimus or ciclo-
sporin following primary liver transplant. A Bayesian NMA was conducted to evalu-
ate likelihood of death, graft loss, and acute rejection (AR) at 12 months. Outcomes 
were adjusted for recipient gender and age, hepatitis C (HCV) status, hepatocellular 
carcinoma, mycophenolate mofetil, azathioprine, and steroid use. RESULTS: Head-
to-head study results were available for ciclosporin versus IR tacrolimus (n= 14) and 
PR tacrolimus versus IR tacrolimus (n= 2). Relative to ciclosporin, IR and PR tacrolimus 
were associated with reduced likelihood of death within 12 months of transplant 
(median odds ratios [OR] of 0.78 and 0.60, respectively). Mortality outcomes were 
superior with PR versus IR tacrolimus (median OR of 0.76). AR was less common with 
IR tacrolimus compared with ciclosporin (median OR of 0.69), whereas limited data 
for PR tacrolimus was evidenced by large credible intervals. There were no significant 
differences with respect to graft loss. Sensitivity analyses indicated that results were 
robust to assumptions and changes in confounders. Confounder analysis found that 
patient age was associated with death, whereas HCV status was associated with AR 
and graft loss. CONCLUSIONS: Patient and treatment factors beyond immunosup-
pressive treatment influence outcomes. Results of this confounder-controlled analysis 
provide further evidence that tacrolimus has substantial benefits over ciclosporin 
in liver transplant recipients. Compared with IR tacrolimus, data indicate that PR 
tacrolimus is superior with respect to patient survival.
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OBJECTIVES: Several meta-analyses comparing ciclosporin with tacrolimus have 
been conducted since the 1994 publication of the tacrolimus registration trials, 
but most captured data from randomized controlled trials (RCTs) predate recent 
improvements in waiting list prioritization, induction protocols and concomitant 
medications. The present study comprised a systematic review, meta-analysis 
and indirect treatment comparison of ciclosporin, immediate-release (IR) and 
prolonged-release (PR) tacrolimus in liver transplant recipients using studies pub-
lished since January 2000. METHODS: Searches of PubMed, the Cochrane Library 
and EMBASE identified RCTs comparing IR tacrolimus with PR tacrolimus or ciclo-
sporin as the immunosuppressant in primary liver transplant recipients, published 
between January 2000 and August 2014. A random effects meta-analysis was con-
ducted to evaluate the relative risk of death, graft loss, acute rejection (AR), new-
onset diabetes after transplantation (NODAT) and hypertension with IR tacrolimus 
relative to ciclosporin at 12 months. An indirect comparison was then conducted 
between PR tacrolimus and ciclosporin. RESULTS: The literature search identified 
12 RCTs comparing ciclosporin with IR tacrolimus and one RCT comparing IR with 
PR tacrolimus. Relative to ciclosporin, IR and PR tacrolimus were both associated 
with significantly improved outcomes in terms of patient survival (risk ratios [RR] 
of 1.27; 95% confidence interval [95%CI] 1.03–1.57 and 1.27; 95%CI 1.02–1.58, respec-
tively). IR tacrolimus was superior to ciclosporin in terms of hypertension (RR 1.26; 
95%CI 1.12–1.42). There were no significant differences between ciclosporin and IR 
tacrolimus in terms of graft loss, AR or NODAT. CONCLUSIONS: Meta-analysis of 
RCTs published since 2000 showed IR and PR tacrolimus to be superior to ciclosporin 
in terms of patient survival and hypertension, while no significant differences were 
identified in terms of graft loss, AR or NODAT. These findings provide further evi-
dence supporting the use of tacrolimus as the cornerstone of immunosuppressive 
therapy in liver transplant recipients.
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OBJECTIVES: Helicobacter pylori (HP) is prime cause of the upper gastrointestinal 
(UGI) diseases, including certain cancers. The standard triple therapy (TT) (one pro-
ton pump inhibitors (PPI) and two antibiotics) is available for the eradication of H. 
pylori but due to the increased adverse drug reactions (ADRs), poor compliance, and 
growing antibiotic resistant, simple dual therapy (DT) (one PPI and one antibiotic) 
was introduced. But there is a conflict regarding the use of dual vs TT. Present meta-
analysis is aimed at exploring effectiveness of dual versus TT for eradication of 
HP. METHODS: Randomized clinical trials (RCTs) assessing effectiveness of DT vs TT 
in confirmed HP positive cases with minimum of 4 week post-treatment follow-up 
results were included. Literature search was done using appropriate MeSH terms. 
Full text articles published in English having complete data were included. Effect 
estimate was presented as risk ratio (Rr). Assessment of heterogeneity was done 
using Cochran Q and I2 tests. We pooled effectiveness and ADRs using random effect 
